Related by context. All words. (Click for frequent words.) 82 Submits Biologics License Application 82 Completes Patient Enrollment 81 Initiates Phase II 81 Initiates Phase III 81 Receives Orphan Drug Designation 81 Initiates Clinical Trial 80 Files IND 80 Receives Approvable Letter 80 Announces Tentative Approval 80 Initiates Enrollment 79 Receives Milestone Payment 79 Submits NDA 78 Receive Milestone Payment 78 Drug Fails 78 Initiates Clinical 78 Submits IND 78 Begins Dosing 77 Licenses Novel 77 Initiates Dosing 77 Oral Calcitonin 77 Receives Tentative Approval 77 Presents Positive 77 FDA Clears 77 Presents Preclinical Data 76 Submits Response 76 Meets Primary Endpoint 76 Announce License Agreement 76 Teva Provides Update 76 Launches Generic Version 76 Announce Licensing Agreement 76 Drug Candidate 76 Receives Fast Track 75 PRN FDA Approves 75 Sign License Agreement 75 Granted Orphan Drug 75 Announce Collaboration Agreement 75 Receives Orphan Drug 75 Develop Novel 75 Arthritis Drug 75 FDA Accepts 75 Enrolls First 75 Successfully Completes Phase 75 IG HCR ;) CO 75 Completes Enrollment 75 Extends Collaboration 75 Commences Phase 75 Taro Receives 74 Receives Favorable 74 Completes Dosing 74 Demonstrates Significant 74 Receives CE Marking 74 Files Investigational 74 Achieves Primary Endpoint 74 Submits Application 74 Therapeutic Competitors Companies 74 Mylan Receives Approval 74 Initiate Phase III 74 Vitrasert R 74 Gets FDA Clearance 74 Submits Supplemental 74 Begins Shipment 74 Psoriasis Drug 74 Investigational Oral 74 Receives Complete Response 74 Demonstrates Positive 73 Sign Licensing Agreement 73 Receives Tentative FDA 73 Presents Preclinical 73 Announces FDA Clearance 73 Reveals Positive 73 Drug Shows Promise 73 Earns Milestone Payment 73 Generic Versions 73 FDA Okays 73 Initiates Clinical Trials 73 Prostate Cancer Vaccine 73 Amends Agreement 73 Lung Cancer Drug 73 Reacquires 73 Licenses Patents 73 Shows Efficacy 73 Vaccine Adjuvant 73 Milestone Payment From 73 IND Application 73 Announces Licensing Agreement 73 Initiates Phase 2b 73 Initiate Clinical Trial 73 Announces License Agreement 73 FDA Approvals 73 NDA Submission 73 Generic Version 73 Merck Serono Nycomed 73 Flamel Technologies Announces 73 Presents Positive Preclinical 72 Investigational Compound 72 Therapeutic Competitors Report 72 Receives Clearance 72 Present Preclinical Data 72 Patients Treated With 72 Merck OSI Pharmaceuticals 72 Milestone Payment 72 Announce Merger Agreement 72 pharmacogenomic translational research 72 Obtains Approval 72 Announces Initiation 72 Terminate Merger Agreement 72 Novel Oral 72 Therapeutic Competitors companiesandmarkets.com adEgemonye 72 Rheumatoid Arthritis Drug 72 Lupus Drug 72 Transdermal Patch 72 Reports Preclinical Data 72 Improves Survival 72 Pharma Merck Serono 72 Receives Positive Opinion 72 Achieves Milestone 71 DP VPA 71 VIVUS Announces 71 gets USFDA nod 71 Immunomedics Announces 71 Announces Favorable 71 Initiate Phase 71 Milestone Payments 71 Osteoporosis Drug 71 Announce Initiation 71 Voluntarily Withdraws 71 Investigational Treatment 71 Demonstrates Potential 71 Prolongs Survival 71 Completes Previously Announced 71 Phase 2b Clinical Trial 71 Receives Conditional 71 Epilepsy Drug 71 Pegloticase 71 Inc Therapeutic Competitors 71 Systemic Delivery 71 Generic Version Of 71 Shows Promise Against 71 Significantly Improves 71 Obtains License 71 Expanded Indication 71 Receives Favorable Ruling 71 Successfully Completes Tender Offer 71 Grants Orphan Drug 71 R lenalidomide 71 Confirms Efficacy 71 Voluntarily Withdraw 71 markets HP Acthar 71 Begin Clinical Trials 71 Receives FDA Clearance 71 JAK2 Inhibitor 71 Tibotec BVBA 71 Drug Maker 70 Recommends Approval 70 Shows Promising 70 Fast Track Status 70 Identifies Potential 70 Announce Commencement 70 Files Patent Application 70 FDA APPROVES 70 Patient Enrollment 70 Files Shelf Registration Statement 70 FDA Approves Generic 70 platform HDL Mimetic 70 Crofelemer budesonide foam 70 Amend Merger Agreement 70 Boehringer Ingelheim MedImmune 70 Patent Covering 70 Trial Evaluating 70 Receives Approval From 70 Genentech Wyeth Pharmaceuticals 70 AVI BioPharma Announces 70 Pruvel TM 70 GlaxoSmithKline MedImmune 70 Phase III Clinical Trial 70 Pivotal Study 70 Signs Licensing Agreement 70 Terminates Agreement 70 Supplemental Biologics License Application 70 Vaccine Protects Against 70 Schizophrenia Drug 70 Spectrum Pharmaceuticals Announces 70 Receives Positive 70 Announce Licensing 70 Announces Discontinuation 70 Significantly Reduces 70 Announces Poster Presentations 70 Submits Investigational 70 Cholesterol Drug 70 Collaborators Publish 70 Reveals Receipt 70 Receives Unsolicited 70 Xcytrin R 70 Gout Drug 70 Phase 2a Trial 70 Completes Tender Offer 70 Exercises Option 70 Migraine Drug 70 Receives SFDA Approval 70 Anti Tumor 70 Namenda Memantine HCl 70 Receives Patent 70 Kosan dependence 70 Inc. www.micromet inc.com 70 Nanophase Announces 70 R MSCRAMM 70 Initiates Phase 70 Paris IPN Euronext 70 proprietary radiolabeled monoclonal 70 Cholesterol Lowering Drug 70 TELINTRA R 70 Novartis Novo Nordisk 70 Clinical Trial Results 70 Extend Collaboration 70 Idenix Novartis 69 Q1 Loss Narrows 69 Announce Receipt 69 Announces Dismissal 69 Blood Thinner 69 Commercialize Novel 69 Closes Previously Announced 69 Shows Promise 69 Collaborators Present 69 Begins Clinical Trial 69 Settle Patent Litigation 69 Rotavirus Vaccine 69 Announces Dosing 69 Develops Novel 69 STERIS Corporation Announces 69 Proven Effective 69 INSPIRE Trial Phase III 69 PDL BioPharma Announces 69 GlaxoSmithKline Biologicals SA 69 Telik Announces 69 COLAZAL R 69 Kinase Inhibitor 69 Ondansetron Orally Disintegrating Tablets 69 Reports Positive 69 Signs License Agreement 69 candidates Azedra TM 69 Announce Expiration 69 Dementia Related Psychosis 69 Shows Statistically Significant 69 Regains Full 69 Gets Favorable 69 Oral Suspension USP 69 Resubmits 69 Announces Successful Completion 69 GTC recombinant form 69 Single Dose 69 Viagra Soft Cialis Soft 69 pralatrexate injection folate analogue 69 Provides Update Regarding 69 Discontinues 69 Biogen Genentech 69 Reduces Risk 69 MOVIPREP R 69 Phase IIb Trial 69 Combination REOLYSIN R 69 Board Unanimously Rejects 69 initiated Phase Ib 69 Novel Therapeutic 69 Molecular Diagnostic Test 69 Multiple Ascending Dose 69 Demonstrates Sustained 69 Completes Merger With 69 novel orally inhaled 69 Terminates Contract 69 methylnaltrexone bromide 69 Nicotine Vaccine 69 Board Authorizes 69 Abstract Accepted 69 Phase 2b Trial 69 novel emulsion formulation 69 FDA Approves 69 Issued Patent 69 FDA Panel Recommends 69 Genentech sanofi aventis 69 Awarded Qualifying Therapeutic 69 Acquires Exclusive 69 Successfully Concludes 69 Telik logo TELINTRA 69 Shareholders Approve Acquisition 69 Anticancer Drug 69 Settle Patent Dispute 69 Settles Litigation 69 Significantly Increases 69 BioDelivery Sciences Announces 69 Nasdaq XTLB 69 Novartis Organon 69 Phase III Trial 69 Small Molecule 69 Neulasta R 69 Personalized Immunotherapy 69 Seeks Approval 69 Potent Antiviral Activity 69 Announces Issuance 69 Adjuvant Treatment 68 Study Demonstrates 68 Advanced Melanoma 68 Wins Approval 68 NYSE WYE 68 Commence Phase 68 Obtains Exclusive License 68 Avian Influenza Vaccine 68 developing Zerenex ferric 68 Improves Outcomes 68 Pivotal Phase III 68 Q3 Loss Widens 68 CysDisplay R 68 Recombinant Human 68 please visit http:/www.vandapharma.com 68 Antifungal 68 Testosterone Gel 68 Recombinant Protein 68 Biomarker Study 68 RNAi Therapeutics 68 MEDAREX 68 First Patient Enrolled 68 Clarifies Status 68 Announces Publication 68 SPRYCEL ® 68 Receives Regulatory 68 Ondansetron Injection 68 DOR BioPharma Announces 68 RNAi Therapeutic 68 Misonix Announces 68 TRACON Pharmaceuticals 68 Successfully Closes 68 Demonstrates Statistically Significant 68 Severe Sepsis 68 Bradmer Pharmaceuticals 68 Effectively Treats 68 Adjunctive Therapy 68 Alnylam Nasdaq ALNY 68 Aradigm Logo 68 Enters Into Collaboration 68 HIV treatments Reyataz 68 Phase IIb Clinical Trial 68 HuMax TAC 68 Taiho Pharmaceutical 68 Lorus Therapeutics Announces 68 Becton Dickinson BD 68 Xeloda ® 68 Q4 Loss Widens 68 Obtains Exclusive Rights 68 PFIZER INC. 68 Secures Financing 68 Regains NASDAQ 68 Patients Receiving 68 Protease Inhibitor 68 Restructures Operations 68 Introduces Novel 68 Aztreonam Lysine 68 Announces Stockholder Approval 68 Commences Phase III 68 Aeolus Pharmaceuticals Announces 68 Study Evaluating 68 Luveris R Ovidrel R 68 Generic Protonix 68 Paliperidone Palmitate 68 submitted Biologics License 68 Nabi HB R 68 Phase IIa Clinical Trial 68 FDA Warns 68 Agonist MABA program 68 vapreotide acetate 68 includes Dideco CarboMedics 68 Awarded Patents 68 Positive Opinion 68 R Saizen R 68 Resubmission 68 acetonide FA 68 Lowers Risk 68 Withdraws Application 68 non nucleoside inhibitor 68 Mg Usa 68 HCV RNA polymerase 68 Metabolic Disorder 68 Crucell Announce 68 Strengthens Position 68 Confirmatory Phase 68 Seasonal Influenza Vaccine 68 Bazedoxifene 68 Inc. Nasdaq OXGN 68 Nasdaq MNKD focuses 68 estrogen receptor beta agonist 68 Levoleucovorin 68 please visit www.abraxane.com 68 Data Suggest 68 Vicriviroc 68 Successfully Treats 67 S. Arzerra 67 SPL# Gel vaginal microbicide 67 Receives NASDAQ 67 Peginterferon alfa 2b 67 Hydrochlorothiazide Tablets 67 Million Milestone Payment 67 markets COLAZAL 67 Immunotherapeutic 67 PF # [002] 67 Receives Approvals 67 Tezampanel 67 antibiotics Cipro 67 Hsp# Inhibitor 67 Aloprim TM allopurinol sodium 67 Vitrasert ® 67 Release Capsules 67 AUDIO PROVIDED BY 67 NICE Recommends 67 Ltd Therapeutic Competitors 67 Empatic ™ 67 Crit Rev 67 Blood Pressure Drug 67 Cypher Sirolimus 67 Dose Ranging Study 67 IMiDs ® 67 nasal calcitonin product 67 HER2 Positive 67 SIX RO ROG 67 Orally Active 67 Patent Issued 67 mesylate tablets approved 67 Terminates Merger Agreement 67 TRANSDUR ® 67 MKC# MT 67 Quinapril 67 Q2 Adj 67 Treximet ® 67 HCV Protease Inhibitor 67 Obtains FDA 67 Announce Settlement 67 Mutually Agree 67 Roche OTC RHHBY 67 Announces Termination 67 Finalizes Acquisition 67 Topiramate Tablets 67 ANDA Filing 67 FACTIVE ® 67 Nasdaq MNKD focused 67 euro adhoc Intercell AG 67 Desvenlafaxine 67 Receives Marketing Authorization 67 ® bortezomib 67 Transgenomic Pharmacogenomics Services 67 Anti Inflammatory 67 TRANSDUR ™ 67 markets Testim ® 67 Pafuramidine 67 ELADUR TM 67 SinuNase ™ 67 ® lenalidomide 67 Signs Merger Agreement 67 SABER ™ 67 successfully commercialize Iluvien 67 diarrhea fatigue asthenia 67 Sangamo BioSciences Announces 67 cytomegalovirus immune globulin 67 AVANIR Pharmaceuticals Announces 67 FY# Loss Widens 67 ® adefovir dipivoxil 67 Mg Uk 67 Agenerase 67 Fluconazole 67 Slows Progression 67 Aloxi ® 67 LSE SHP.L 67 Jumps Higher 67 Wins Patent Infringement 67 Clinical Trial Evaluating 67 Announce Definitive Agreement 67 Exclusive License 67 Q3 Loss Narrows 67 5 lipoxygenase activating 67 Inhaled Insulin 67 Announce Launch 67 Onyx Pharmaceuticals Announces 67 Issues Guidance 67 Announce Collaboration 67 Reduces Mortality 67 Anemia Drug 67 Gets Tentative 67 Reconfirms 67 Receives Notification 67 Unsolicited Proposal From 67 Nitazoxanide 67 developing ACAPODENE 67 Diagnostic Tests 67 MEK Inhibitor 67 Enters Into Licensing Agreement 67 Study Showed 67 Fentanyl Patch 67 Previously Treated 67 Expand Collaboration 67 Q4 Loss Narrows 67 Ecallantide 67 Transcept Pharmaceuticals 67 Gonal f R follitropin 67 phase III isavuconazole 67 Consummates 67 KRYSTEXXA TM pegloticase 67 MCSP respectively 67 Nasdaq AVNC 67 TM Aganocide 67 Patents Covering 67 Intravenous Human 67 Disease Modifying 67 Achieves Significant 67 Derma Sciences Announces 67 Doripenem 67 OTC RHHBY 67 Lanthanum Carbonate 67 Sinks Lower 67 Contaminant Found 67 Receives Authorization 67 highly purified pasteurized 67 Atypical Antipsychotic 67 MBRX 67 Successfully Completes Acquisition 67 Announces Effective Date 67 proprietary intravenous formulation 67 Announces Presentation 67 FY# Loss Narrows 67 Arno Therapeutics 67 Desvenlafaxine Succinate 67 Subsidiary Enters 67 Xoma Ltd 67 Explores Strategic Alternatives 67 Concludes Acquisition 67 FDA Warns Against 67 therefore therapeutically equivalent 67 Successfully Treated 67 Gonal f R 67 Q1 Loss Widens 67 Expands Scope 67 molecular therapeutics immunotherapies 67 Announces Signing 67 Appoints Experienced 67 Reports Receipt 67 CIMZIA r 66 OMRIX Biopharmaceuticals 66 Completes Initial 66 Gentamicin Surgical Implant 66 Broadens Scope 66 R sorafenib tablets 66 Demonstrates Efficacy 66 Files Provisional 66 Torisel temsirolimus 66 Q2 Loss Widens 66 Risperidone Oral Solution 66 Tumor Targeting 66 Expands Scientific Advisory 66 TKPHF 66 Sagent Pharmaceuticals Announces 66 oncolytic virus therapies 66 Sign Definitive Agreement 66 rasagiline tablets 66 AstraZeneca AZN.L 行情 66 Hematological Malignancies 66 Q2 Loss Narrows 66 Updates Status 66 Stockholders Approve Acquisition 66 erlotinib Tarceva R 66 sanofi aventis Bayer Schering 66 Romidepsin 66 NASDAQ PPDI 66 Staphylococcus aureus Immune Globulin 66 Obtains CE Mark 66 Maribavir 66 RANK Ligand inhibitor 66 Tramiprosate ALZHEMED TM 66 DARA logo 66 selective estrogen receptor modulator 66 LymphoStat B TM 66 Commercializes 66 Therapeutic Antibody 66 Myriad logo BRACAnalysis 66 Announcement acc 66 BioGlue R 66 IND Filing 66 Prove Effective 66 Signs Agreements 66 Campto 66 Treatment Reduces 66 Announces Underwriters Exercise 66 Antithrombin 66 Unigene nasal calcitonin 66 Bosutinib 66 Sumatriptan Succinate 66 Veronate R 66 R bendamustine hydrochloride 66 Genotyping Test 66 equine osteoarthritis marketed 66 Bertek Pharmaceuticals 66 Announce Shareholder Approval 66 NASDAQ RNAI 66 lead molecular radiotherapeutic 66 Novel Vaccine 66 Norgine BV 66 Injection Site 66 NSE SUNPHARMA 66 molecular imaging radiopharmaceutical 66 Attenuates 66 include ClindaReach TM 66 Study Shows Benefits 66 Nasdaq PGNX 66 ΞΕΝΗ ΔΗΜΟΣΙΕΥΣΗ ΑΝΑΚΟΙΝΩΣΗInfosys Finacle 66 Confirms Commitment 66 Preclinical Data 66 Kuvan R 66 Diabetic Foot Ulcer 66 lexidronam injection 66 Executes Agreement 66 ALN HPN 66 Bristol Myers Squibb Celgene 66 BRILINTA 66 Announces Definitive Agreement 66 Strengthens Balance Sheet 66 Tibotec Therapeutics division 66 Wyeth Enbrel 66 Treatment Shows Promise 66 Settles Patent Dispute 66 Diabetic Neuropathy 66 Cephalon GlaxoSmithKline Schering Plough 66 evaluating picoplatin 66 Lamotrigine Tablets 66 visit www.genenews.com 66 anti botulism antibody 66 LymphoStat B belimumab 66 XL# anticancer compounds 66 Issues Complete Response 66 Germany FSE SCH 66 liver resection surgeries 66 Acute Exacerbations 66 Welcomes Analyst Initiation 66 agonistic human 66 Oncology Compounds 66 ATRA IV 66 commercializing Loramyc ® 66 VISICOL R 66 ORADUR ® 66 Announces Divestiture 66 Completes Financing 66 Renal Cancer 66 Japanese Encephalitis Vaccine 66 Liprotamase 66 interferon gamma 1b 66 visit www.noven.com 66 FS Antihemophilic Factor Recombinant 66 Signs Non Binding 66 ARRY # 66 Completes Restructuring 66 Amigal TM 66 personalized dendritic 66 Patient Enrolment 66 Inc. OTCBB BCLI 66 Medicure Announces 66 Entry Inhibitor 66 Horizant ™ 66 SpeBio joint venture 66 Pooled Analysis 66 Dynepo TM 66 exclusive sublicense 66 Completes Recapitalization 66 Novel Compound 66 Files Patent 66 Copegus R 66 Indevus Pharma 66 OMAPRO ™ 66 NEBIDO VANTAS SUPPRELIN LA 66 Preliminary Injunction Against 66 Tyrosine Kinase Inhibitor 66 Pancreas Cancer Vaccine 66 Receives Clearance From 66 technology visit http:/www.genmab.com 66 TriPath Oncology 66 Subsidiary Completes 66 sapropterin dihydrochloride 66 BioElectronics Announces 66 Hepatitis B Vaccine 66 PDUFA Date 66 Announces Commencement 66 Smallpox Vaccine 66 Broadens Its 66 Medoro Resources Announces 66 Cephalon GlaxoSmithKline 66 progressive metastatic prostate 66 Humanized Anti 66 hyaluronidase enzyme 66 WeissComm Partners +#-#-#-# 66 Patent Lawsuit 66 Announces Positive 66 Combination Treatment 66 Settles Patent Litigation 66 BUPHENYL R 66 Test Detects 66 Selective Electrochemical Tumor Ablation 66 Ercole Biotech 66 Nasdaq ANPI 66 Interferon Alpha 66 Sign Definitive Merger 66 Colaris Colaris AP 66 Oxcarbazepine 66 Metformin HCl 66 Backs FY# Outlook 66 Receives Subpoena 66 Weight Loss Drug 66 Closes Second Tranche 66 Orphan Status 66 Vascular Disrupting Agent 66 First Patient Treated 66 please visit www.eisai.com 66 Small Molecule Drug 66 CD# CEA 66 Unanimously Recommends Approval 66 telomerase therapeutic 66 Therapeutic Vaccine 66 GVAX ® 66 Completes Patient Enrolment 66 Emtriva Viread 66 Million Doses 66 Announce Early Termination 66 Retains CCG Investor Relations 66 Granulocyte Colony Stimulating Factor 66 Finalizes Purchase 66 Nasdaq EPCT 66 Receives Shareholder Approval 66 pentadentate logo R 66 Phase III Trials 66 label Lipofen R 66 Enters Into License Agreement 66 combines bupropion 66 Beats Raises Guidance 66 Sensipar ® 66 Ridaforolimus 66 RELOVAIR ™ 66 Exploit collaboration 66 BioElectronics Corporation Announces 66 License Option Agreement 66 Boxed Warnings 66 Q1 Adj 66 Antitumor Activity 66 Initiate Phase II 66 Vaccine Adjuvants 66 HuCAL PLATINUM R 66 Predictive medicine 66 Partnering Agreements 66 Further Validates 66 Secures Patent 66 Inks License 66 Chronic Hepatitis C 66 Zorbtive TM 65 First Patient Dosed 65 Patent Infringement Litigation 65 Vidaza R 65 adenosine injection 65 OTCBB GNTA 65 Explore Strategic Alternatives 65 Roche Boniva 65 Drug Combo 65 ExxonMobil Fluor 65 ELADUR ™ 65 METOZOLV TM ODT metoclopramide 65 novel MetAP 2 65 Megapharm Ltd. 65 NASDAQ XTLB 65 GATTEX TM 65 Valortim TM 65 Signs Purchase Agreement 65 Novel Antibiotic 65 Closes Merger 65 Clinical Study Shows 65 developing Bicifadine serotonin 65 #-# Full Text 65 TNF Blockers 65 Quark Biotech 65 Guidelines Issued 65 PROVENGE ® 65 Medisorb ® 65 PHRM 65 Nipent R 65 Vitamin D analogue 65 NEUPOGEN R 65 COMUNICADO DE 65 Treated Patients 65 Kristalose ® lactulose 65 ® ranolazine extended 65 Ovitrelle R Serostim 65 Refractory Hodgkin Lymphoma 65 4SC AG ISIN DE# 65 Lyophilized 65 Recurrent Breast Cancer 65 Patients Enrolled 65 Argatroban 65 syndrome overactive bladder 65 Integra LifeSciences Announces 65 Consulting Fees Honoraria 65 Patient Treated 65 Zegerid OTC 65 please visit http:/www.atherogenics.com 65 Generic Lovenox 65 Asentar TM 65 Gets Subpoena 65 Anidulafungin 65 Regenerative Cell 65 Aldara ® 65 Boniva ibandronate 65 Node Positive 65 FOLOTYN ® 65 Syndax Pharmaceuticals Inc. 65 Sensipar R 65 topical gel formulation 65 Trastuzumab DM1 65 Restructures Debt 65 Jointly Announce 65 Miraculins Announces 65 Inhibits 65 Receives FDA Approvable 65 Faropenem 65 Showed Significant 65 SYCREST 65 Appears Safe 65 balsalazide disodium Capsules 65 Inflammatory Arthritis 65 Receives Notice Related 65 Plicera TM 65 Isis Pharma 65 Serostim ® 65 Withdraws Proposal 65 TB Vaccine 65 C1 Inhibitor 65 memantine HCl 65 AMEX KAL 65 Acquires Controlling Interest 65 PPD Declares 65 Taglich Brothers Initiates Coverage 65 novel therapeutic antibodies 65 Expands Portfolio 65 Phase 2a Clinical Trial 65 staphylococcal vaccines 65 Febuxostat 65 Therapeutic Competitors 65 epoetin zeta 65 sitaxsentan sodium 65 Copegus ® 65 Inc. Amex PIP 65 Methylphenidate Transdermal System 65 Successfully Completed 65 Amira Pharmaceuticals 65 Announces Shareholder Approval 65 live oral pentavalent 65 Enters Into Exclusive 65 CARBATROL 65 IV Busulfex 65 Preotact R 65 Enters Into Definitive 65 JAK Inhibitor 65 beta 1a 65 Wins Summary Judgment 65 Albugon 65 Preclinical Study 65 VIVITROL ® 65 Announces Cancellation 65 COPEGUS R 65 Vildagliptin 65 Retisert R 65 Anti Infective 65 Clears Path 65 Licensing Deal 65 Temodar ® 65 pioglitazone hydrochloride 65 include Healive TM 65 Provides Shareholder 65 Tibotec Virco 65 Inc. NASDAQ SIRT 65 Inks MOU 65 signal detection CTSD 65 Ebola Vaccine 65 Hormone Refractory Prostate Cancer 65 ergot derivatives 65 Pharmacother 65 5 FU leucovorin 65 Naglazyme R 65 Demonstrates Potent 65 TOPAMAX R 65 Announce Exclusive 65 NexMed Receives 65 IgG1 monoclonal antibody 65 CHEAP ONLINE PHARMACY LOW 65 NerPharMa 65 #.#B Vioxx 65 humanized therapeutic 65 Formalizes 65 Completes Transaction 65 Antidepressant Drug 65 Completes Purchase Of 65 Drug Prevents 65 Bullish Technical Alert 65 Friedreich Ataxia FRDA 65 NASDAQ MNKD focuses 65 Antiviral Drugs 65 Gets Approval 65 Heartburn Drugs 65 SWOT Analysis Aarkstore Enterprise 65 Somatuline Depot 65 Anticancer Compound 65 Acne Medication 65 HYVISC ® treatment 65 Amends Terms 65 palonosetron hydrochloride Injection Dacogen 65 Receives Commitment 65 Investigational Drug 65 AAG geldanamycin analog 65 Femring ® 65 Marketing Authorisation Holder 65 NewsBite Downgrade Puts Pressure 65 Oral Insulin 65 Provides Guidance 65 related CMV Retinitis 65 Am J Obstet 65 Anti Diabetic 65 Closes Oversubscribed 65 peptidic compound 65 Calcium Acetate 65 Tech DVAX 65 NV Organon 65 Phase 1b Clinical Trial 65 ASE SVA 65 Medoxomil 65 Antitumor 65 Confirms Filing 65 BioSante Pharmaceuticals Reports 65 Unveils Revolutionary 65 OSMOPREP TM 65 interferon beta 1a infertility 65 Vertex Pharmaceuticals Announces 65 Therapy Improves 65 Oral Fingolimod 65 Romiplostim 65 aerosolized AAT 65 dependent kinase inhibitor 65 Begins Tender Offer 65 Pending Acquisition 65 ZEFFIX 65 Dyax logo 65 VentiRx Pharmaceuticals 65 Successfully Complete 65 Momenta Pharmaceuticals MNTA 65 Confirms Validity 65 Novel Inhibitor 65 Nasdaq VNDA 65 GTC NASDAQ GTCB 65 Guides Inline 65 Lexapro Effexor Serzone 65 HCl capsules 65 treat chronic sinusitis 65 Accelerate Commercialization 65 Anticancer Agent 65 LifeVantage Announces 65 Cholesterol Lowering 65 Peyronie disease Frozen Shoulder 65 * vwd PRN 65 Develop Next Generation 65 Makes Unsolicited Bid 65 RDYN 65 Commercialize 65 Stem Cell Derived 65 Enters Agreement 65 Inc. www.prometic.com 65 Patent Infringement Case 65 Reaffirms Outlook 65 Collaborates With 65 Directors Unanimously Rejects 65 Sunesis Pharma 65 dihydrochloride Tablets 65 CHMP Opinion 65 Atripla combines 65 Device Maker 65 Captisol enabled 65 Secures Long Term 65 #mg Tablets [002] 65 TURNING INSIGHTS INTO HOPE 65 Generic Lipitor 65 Hematology Molecular Pathology 65 Extends Expiration Date 65 Unveils Groundbreaking 65 itraconazole Sporanox 65 Multaq dronedarone 65 Spins Off 65 Treatment Naïve 65 Announce Completion 65 Panflu TM 65 Pivotal Phase 65 Subsidiary Receives 65 Companion Diagnostic 65 include Altastaph TM 65 candidate deforolimus 65 Regains Compliance With 65 Plaque Psoriasis